Literature DB >> 2579238

The pKa of butaclamol and the mode of butaclamol binding to central dopamine receptors.

F A Chrzanowski, B A McGrogan, B E Maryanoff.   

Abstract

The pKa values for butaclamol (1), 1,2,3,5,6,10b beta-hexahydro-6 alpha-phenylpyrrolo[2,1-alpha]isoquinoline (2, McN-4612-Y), and 2-tert-butyl-1,3,4,6,7,11b beta-hexahydro-7 beta-phenyl-2H-benzo[alpha]quinolizin-2 alpha-ol (3, McN-4171) were determined to be 7.2, 9.1, and 7.0, respectively. The values for 1 and 3 are anomalous; however, the value for 1 (7.2) is not as low as the one reported in the literature (pKa = 5.9). We also determined pKa values for apomorphine, chlorpromazine, and lidocaine, for reference purposes (7.6, 9.2, and 7.9, respectively). The results indicate that 1 would not be predominantly unprotonated under the physiological conditions of receptor binding, rather it would be about 50% protonated. This fact may contravene a suggested binding model used to map the central dopamine receptor (viz., ref 3).

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2579238     DOI: 10.1021/jm00381a022

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  3 in total

1.  Lyophilized Chitosan/xanthan Polyelectrolyte Complex Based Mucoadhesive Inserts for Nasal Delivery of Promethazine Hydrochloride.

Authors:  Mohamed Hassan G Dehghan; Marzuka Marzuka
Journal:  Iran J Pharm Res       Date:  2014       Impact factor: 1.696

2.  Tranylcypromine substituted cis-hydroxycyclobutylnaphthamides as potent and selective dopamine D₃ receptor antagonists.

Authors:  Jianyong Chen; Beth Levant; Cheng Jiang; Thomas M Keck; Amy Hauck Newman; Shaomeng Wang
Journal:  J Med Chem       Date:  2014-06-03       Impact factor: 7.446

3.  The Ascaris suum nicotinic receptor, ACR-16, as a drug target: Four novel negative allosteric modulators from virtual screening.

Authors:  Fudan Zheng; Alan P Robertson; Melanie Abongwa; Edward W Yu; Richard J Martin
Journal:  Int J Parasitol Drugs Drug Resist       Date:  2016-02-10       Impact factor: 4.077

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.